Interleukin 2 News and Research

RSS

Profectus BioSciences commences GENEVAX IL-12 phase 1 study for HIV

Profectus BioSciences, a leader in the development of therapeutic and preventive vaccines against infectious diseases and cancers, and the AIDS Clinical Trials Group announced today the initiation of a phase 1 study of Profectus' multi-antigen HIV plasmid DNA vaccine administered with various doses of GENEVAX™ interleukin-12 pDNA adjuvant and delivered using the electroporation based TriGrid™delivery system developed by Ichor Medical Systems.

6 Jan 2011

FDA awards supplemental approval to support efficacy of ACTEMRA in treating RA

Genentech, Inc., a member of the Roche Group, today announced that the United States Food and Drug Administration has extended the ACTEMRA (tocilizumab, RoACTEMRA in the European Union) label to include inhibition and slowing of structural joint damage, improvement of physical function, and achievement of major clinical response in adult patients with moderately to severely active rheumatoid arthritis, when given in combination with methotrexate.

6 Jan 2011

Quercetin and resveratrol may play an important role in inflammation and insulin resistance

A study was carried out to examine the extent to which quercetin and trans-resveratrol (RSV) prevented inflammation or insulin resistance in primary cultures of human adipocytes treated with tumor necrosis factor-a (TNF-a)-an inflammatory cytokine elevated in the plasma and adipose tissue of obese, diabetic individuals. Cultures of human adipocytes were pretreated with quercetin and trans-RSV followed by treatment with TNF-a. Subsequently, gene and protein markers of inflammation and insulin resistance were measured.

24 Dec 2010

Researchers identify new regulator that play a critical role in B cell development

A team at the Institut de recherches cliniques de Montr-al led by Dr. Tarik M-r-y, President and Scientific Director of the institute and Director of the Hematopoiesis and Cancer research unit, will be publishing an important breakthrough in tomorrow's issue of Immunity, a scientific journal from the Cell Press group. The researchers identified a new regulator playing a critical role in the development B cells, which produce antibodies.

23 Dec 2010

New research sheds light on complex regulatory pathways for effective innate immune system

New research by scientists at the University of California, San Diego School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences reveals that the immune system has an effective backup plan to protect the body from infection when the "master regulator" of the body's innate immune system fails.

21 Dec 2010

EpiCept receives Israeli Ministry of Health approval for Ceplene

EpiCept Corporation today announced that the Israeli Ministry of Health has approved the marketing application for Ceplene®, indicated for remission maintenance and prevention of relapse in adult patients with Acute Myeloid Leukemia (AML) in first remission. Megapharm Ltd. is EpiCept's partner in Israel and upon Ministry of Health approval of labeling and other technical matters the company is expected to launch Ceplene® in the first quarter of 2011.

21 Dec 2010

Profectus' GENEVAX IL-12 pDNA adjuvant improves vaccine-induced response rate in Phase I HIV study

Profectus Biosciences, Inc., a leader in the development of therapeutic and preventive vaccines against infectious diseases and cancers, announced today that its GENEVAX™ IL-12 pDNA adjuvant has significantly improved the vaccine-induced response rate in a Phase I clinical study of an experimental DNA vaccine for the prevention of HIV infection.

15 Dec 2010

Key inhibitory role for IL-1 signaling pathway in human innate immune system

Scientists at the University of California, San Diego School of Medicine have described for the first time a key inhibitory role for the IL-1 signaling pathway in the human innate immune system, providing novel insights into human inflammatory bowel disease (IBD) and potential new treatments.

15 Dec 2010

Drug to reverse immunological decline in aging

UCSF researchers have identified an existing medication that restores key elements of the immune system that, when out of balance, lead to a steady decline in immunity and health as people age.

14 Dec 2010

Phase 2 study data of ALD518 demonstrates reversal of anemia in NSCLC patients

Alder Biopharmaceuticals Inc. today announced that data from a Phase 2 study of its ALD518 investigational antibody therapeutic that targets interleukin-6 (IL-6) demonstrate a reversal of anemia in patients with advanced non-small cell lung cancer.

9 Dec 2010

John Theurer Cancer Center presents research findings at ASH meeting

The John Theurer Cancer Center at Hackensack University Medical Center announced today important research findings presented at the annual meeting of the American Society of Hematology taking place December 4-7, 2010 in Orlando, Florida. The ASH meeting is the world's leading scientific gathering of hematologists and hematology researchers.

7 Dec 2010

Interim results from Cytheris CYT107 Phase I clinical trial in TCD bone marrow transplant patients

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced interim results from a Phase I clinical trial of its investigational drug candidate, recombinant human Interleukin-7 (CYT107), in the treatment of post-transplant patients with T-cell depleted (TCD) bone marrow or peripheral blood stem cell transplants.

7 Dec 2010

Interleukin-1 plays major role in wound healing

Anesthesiologists are playing a leading role in research into the molecular factors affecting inflammation, pain, and healing of surgical incisions, as illustrated by papers published in the December issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

7 Dec 2010

Stemline to feature SL-401 clinical efficacy at ASH Annual Meeting

Stemline Therapeutics, Inc. today announced that two abstracts featuring SL-401 clinical efficacy in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), and pre-clinical activity in chronic myeloid leukemia (CML) have been selected for presentation at the upcoming 52nd Annual Meeting of the American Society of Hematology (ASH) to be held in Orlando, FL from December 4-7, 2010.

2 Dec 2010

Worm eggs may heal ulcerative colitis: Research

A new study involving a man who swallowed worm eggs to relieve symptoms of ulcerative colitis sheds light on how worms promote healing in the intestine. The study, published today in Science Translational Medicine, also identifies potential targets for more conventional ways of treating colitis, an inflammatory bowel disease.

2 Dec 2010

Cytheris' combinational therapy demonstrates possible therapeutic strategy for PML

Cytheris SA, a clinical-stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the publication of a case study report based on successful treatment of Progressive Multifocal Leukoencephalopathy (PML) with combination therapy consisting of two investigational agents, Cytheris' recombinant human interleukin-7 (CYT107) and CMX001, an investigational, oral broad-spectrum antiviral drug (Chimerix, Research Triangle Park, NC) in the Journal of Antimicrobial Chemotherapy.

30 Nov 2010

Cannabis compounds trigger immune cells that promote cancer growth

An international team of immunologists studying the effects of cannabis have discovered how smoking marijuana can trigger a suppression of the body's immune functions. The research, published in the European Journal of Immunology, reveals why cannabis users are more susceptible to certain types of cancers and infections.

25 Nov 2010

Study finds association between personality, cognitive ability and neuroendocrinal dysfunction in exhaustion syndrome

Exhaustion syndrome, also called burnout and exhaustion depression, leaves objectively measurable changes in the brain including reduced activity in the frontal lobes and altered regulation of the stress hormone cortisol. This is shown in a new dissertation from Umeå University in Sweden.

18 Nov 2010

Positive results from XOMA 052 study in patients with uveitis of Behcet's disease

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced additional positive results from an open-label pilot study of XOMA 052 in patients with uveitis of Behcet's disease who were suffering from vision-threatening exacerbations despite maximal doses of immunosuppressive medicines.

10 Nov 2010

ORVACS launches ERAMUNE 01 Phase II study to decrease HIV viral reservoirs

ORVACS has launched a Phase II study designed to test the hypotheses that combination therapy with potent antiviral agents and immunomodulator can lead to a decrease in the HIV viral reservoirs and, ultimately, to eradication of the virus. The study is currently being conducted at clinical sites in France, Spain, Italy, and the United Kingdom.

9 Nov 2010

Interleukin 2 News and Research

Profectus BioSciences commences GENEVAX IL-12 phase 1 study for HIV

FDA awards supplemental approval to support efficacy of ACTEMRA in treating RA

Quercetin and resveratrol may play an important role in inflammation and insulin resistance

Researchers identify new regulator that play a critical role in B cell development

New research sheds light on complex regulatory pathways for effective innate immune system

EpiCept receives Israeli Ministry of Health approval for Ceplene

Profectus' GENEVAX IL-12 pDNA adjuvant improves vaccine-induced response rate in Phase I HIV study

Key inhibitory role for IL-1 signaling pathway in human innate immune system

Drug to reverse immunological decline in aging

Phase 2 study data of ALD518 demonstrates reversal of anemia in NSCLC patients

John Theurer Cancer Center presents research findings at ASH meeting

Interim results from Cytheris CYT107 Phase I clinical trial in TCD bone marrow transplant patients

Interleukin-1 plays major role in wound healing

Stemline to feature SL-401 clinical efficacy at ASH Annual Meeting

Worm eggs may heal ulcerative colitis: Research

Cytheris' combinational therapy demonstrates possible therapeutic strategy for PML

Cannabis compounds trigger immune cells that promote cancer growth

Study finds association between personality, cognitive ability and neuroendocrinal dysfunction in exhaustion syndrome

Positive results from XOMA 052 study in patients with uveitis of Behcet's disease

ORVACS launches ERAMUNE 01 Phase II study to decrease HIV viral reservoirs

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News